Polymyxin B,which is a last-line antibiotic for extensively drug-resistant Gram-negative bacterial infections,became available in China in Dec.2017.As dose adjustments are based solely on clinical experience of risk t...Polymyxin B,which is a last-line antibiotic for extensively drug-resistant Gram-negative bacterial infections,became available in China in Dec.2017.As dose adjustments are based solely on clinical experience of risk toxicity,treatment failure,and emergence of resistance,there is an urgent clinical need to perform therapeutic drug monitoring(TDM)to optimize the use of polymyxin B.It is thus necessary to standardize operating procedures to ensure the accuracy of TDM and provide evidence for their rational use.We report a consensus on TDM guidelines for polymyxin B,as endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society.The consensus panel was composed of clinicians,pharmacists,and microbiologists from different provinces in China and Australia who made recommendations regarding target concentrations,sample collection,reporting,and explanation of TDM results.The guidelines provide the first-ever consensus on conducting TDM of polymyxin B,and are intended to guide optimal clinical use.展开更多
To the Editor:Gastric cancer is one of the most commonly diagnosed cancers in the world.For patients with a pathological tumor-node-metastasis stage of II or III,postoperative adjuvant chemotherapy is generally requir...To the Editor:Gastric cancer is one of the most commonly diagnosed cancers in the world.For patients with a pathological tumor-node-metastasis stage of II or III,postoperative adjuvant chemotherapy is generally required to reduce recurrence risk by controlling residual tumor cells following curative resection.[1]Although taxanes have recently shown promising activity in gastric cancer,[2,3]non-responders may incur costs and experience adverse reactions without clinical benefit,and efforts to select effective regimens for individuals are very important.The application of in vitro chemosensitivity assays as predictive markers in personalized cancer treatment has been investigated in several studies.[4]However,the heterogeneity of the gastric cancer response to taxane-based chemotherapy and the correlation between in vitro chemosensitivity and clinical outcomes remain unclear.展开更多
基金the Shanghai Leading Talents Award,Shanghai Municipal Health Commission(No.LJ2016-01)the Clinical Research Plan of Shanghai Hospital Development Center(No.SHDC2022CRW004)。
文摘Polymyxin B,which is a last-line antibiotic for extensively drug-resistant Gram-negative bacterial infections,became available in China in Dec.2017.As dose adjustments are based solely on clinical experience of risk toxicity,treatment failure,and emergence of resistance,there is an urgent clinical need to perform therapeutic drug monitoring(TDM)to optimize the use of polymyxin B.It is thus necessary to standardize operating procedures to ensure the accuracy of TDM and provide evidence for their rational use.We report a consensus on TDM guidelines for polymyxin B,as endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society.The consensus panel was composed of clinicians,pharmacists,and microbiologists from different provinces in China and Australia who made recommendations regarding target concentrations,sample collection,reporting,and explanation of TDM results.The guidelines provide the first-ever consensus on conducting TDM of polymyxin B,and are intended to guide optimal clinical use.
基金National Key New Drug Creation Special Programs(No. 2017ZX09304-021)Science and Technology Plan of Suzhou(No. SYSD2017151)
文摘To the Editor:Gastric cancer is one of the most commonly diagnosed cancers in the world.For patients with a pathological tumor-node-metastasis stage of II or III,postoperative adjuvant chemotherapy is generally required to reduce recurrence risk by controlling residual tumor cells following curative resection.[1]Although taxanes have recently shown promising activity in gastric cancer,[2,3]non-responders may incur costs and experience adverse reactions without clinical benefit,and efforts to select effective regimens for individuals are very important.The application of in vitro chemosensitivity assays as predictive markers in personalized cancer treatment has been investigated in several studies.[4]However,the heterogeneity of the gastric cancer response to taxane-based chemotherapy and the correlation between in vitro chemosensitivity and clinical outcomes remain unclear.
